NDAOPHTHALMICOINTMENT
Approved
Nov 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
GARAMYCIN (gentamicin sulfate) by Merck & Co. is clinical pharmacology gentamicin sulfate is a wide spectrum antibiotic that provides highly effective topical treatment in primary and secondary bacterial infections of the skin. First approved in 1970.
Drug data last refreshed 8h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GARAMYCIN (gentamicin sulfate) is a broad-spectrum aminoglycoside antibiotic available as an ophthalmic ointment for topical treatment of primary and secondary bacterial skin infections. It works by inhibiting bacterial protein synthesis and is effective against gram-positive bacteria (Staphylococcus aureus, Streptococci) and gram-negative organisms (Pseudomonas aeruginosa, E. coli, Proteus, Klebsiella). The drug has been indicated for pneumonia treatment and is commonly used 3-4 times daily for rapid lesion clearance in impetigo and other dermatologic infections.
LOE Approaching
Product is in late-stage lifecycle with LOE approaching, indicating reduced commercial investment and team consolidation.
Mechanism of Action
CLINICAL PHARMACOLOGY Gentamicin sulfate is a wide spectrum antibiotic that provides highly effective topical treatment in primary and secondary bacterial infections of the skin. Gentamicin Sulfate Cream may clear infections that have not responded to treatment with other topical antibiotic agents.…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on GARAMYCIN offers limited career growth due to LOE-approaching status and minimal commercial investment; roles focus on legacy brand management, cost containment, and transition planning. This is a consolidation phase rather than a growth opportunity.
Worked on GARAMYCIN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.